Temozolomide

Temozolomide has been studied in 20 papers since 2016: 5 observational studies in people, 3 in animals, 8 in cells, 3 reviews; 5 in the past year. It is an approved medicine. The newest story, Nov 15, 2026: “Older mice had shorter survival with human brain tumors”.

InterventionApproved 1999

20 papers study it13 more mention it4 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 29% faster than aging research as a whole: 14 papers in the latest year counted

1 new paper in 30 daysSee all 33 papers on temozolomide

At a glance

The findings reach cells, none yet in people. 3 independent labs in 3 countries; 788 trials, 2 about aging, 273 with no results posted.

None of its findings points the other way.

Cells: a single group. Worms or flies, mice and humans: nothing yet.
  • 3 independent labs in 3 countries
  • 788 trials, 2 about aging, 273 with no results posted
  • Funders: Deutsche Forschungsgemeinschaft and 6 more
  • 31 of 788 trials sponsored by its developers
  • Humans5
  • Animals3
  • Cells8

What did studies of temozolomide find?

3

Studies of temozolomide measured 3 outcomes: cellular senescence, mesenchymal stem cell functionality and YY1.

Cellular senescence

upin human cells1upin humans1

2 studies
  1. Temozolomide induces cellular senescence in human glioblastoma spheroids.

    Cellsin human glioblastoma spheroidsglioblastoma

  2. Temozolomide induces cellular senescence in glioblastoma cells.

    Reviewin glioblastoma cells

More on Cellular senescence

Mesenchymal stem cell functionality

no changein human cells1

1 study
  1. Temozolomide showed no clear effect on mesenchymal stem cell functionality in human cells (highest clinically relevant dose).

    Cellshighest clinically relevant dosebone marrow100 μM

YY1

upin human cells1

1 study
  1. Temozolomide induces YY1 in human cells.

    Cells

More on YY1

Has temozolomide been tested in people?

2 of 788 about aging

Yes: 5 observational studies in people have been published, and 788 trials are registered.

Approved

  • EMA Temodal

    Jan 26, 1999Glioma, Glioma, Malignant, Newly Diagnosed Glioblastoma Multiforme, Patients With Newly Diagnosed Glioblastoma

  • FDA Temodar

    Aug 11, 1999DiscontinuedAnaplastic Astrocytoma, Newly Diagnosed Glioblastoma

  • FDA Temodar

    Feb 27, 2009Anaplastic Astrocytoma, Newly Diagnosed Glioblastoma

  • EMA Temomedac

    Jan 25, 2010Glioma, Glioma, Malignant, Newly Diagnosed Glioblastoma Multiforme, Patients With Newly Diagnosed Glioblastoma

  • EMA Temozolomide Teva

    Jan 28, 2010Glioma, Glioma, Malignant, Newly Diagnosed Glioblastoma Multiforme, Patients With Newly Diagnosed Glioblastoma

  • EMA Temozolomide Accord

    Mar 15, 2010Glioma, Glioma, Malignant, Newly Diagnosed Glioblastoma Multiforme, Patients With Newly Diagnosed Glioblastoma

All 9

Repurposing

40 of 99

Every condition in trials

  • Gliosarcoma

    Phase 3Completed112 trials

  • Diffuse intrinsic pontine glioma

    Phase 3Status unknown13 trials

  • Choroid Plexus Neoplasms

    Phase 3Terminated10 trials

  • Rhabdoid tumor

    Phase 3Status unknown8 trials

  • Ganglioneuroblastoma

    Phase 3Recruiting4 trials

  • Neuroectodermal Tumors, Primitive, Peripheral

    Phase 3Terminated4 trials

40 of 58

Stopped

  • NCT00020839TerminatedMelanoma

    low accrual

  • NCT03495921TerminatedEwing sarcoma

    Slow accrual and as a result, a strategic business decision was made to terminate enrollment.

  • NCT01014767TerminatedChoroid Plexus Neoplasms

    PI departure from coordinating institution

  • NCT00638963TerminatedBreast neoplasm

    Terminated due to poor accrual

  • NCT00004106TerminatedLymphoma

    Per Data Monitoring Committee given the poor/inadequate accrual.

  • NCT00248534TerminatedLymphoma

    slow accrual/lack of resources/low priority due to combining 2 consortia

All 24

Who is developing temozolomide?

3 companies: Black Diamond Therapeutics, ZSky Biotech and Oblato.

Companies
  • Black Diamond TherapeuticsPhase 2glioblastoma, newly diagnosed glioblastoma
  • ZSky BiotechPhase 2glioblastoma
  • OblatoPhase 2recurrent malignant glioma, brain glioblastoma

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 3Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 0Nov 2026: 17 papers in 12 months
Neuro-Oncology

Older mice had shorter survival with human brain tumors

Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.

Mouse studyInterventions

See all 33 papers on temozolomide